𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment outcome for metastatic papillary renal cell carcinoma patients

✍ Scribed by Ellen A. Ronnen; G. Varuni Kondagunta; Nicole Ishill; Lesley Spodek; Paul Russo; Victor Reuter; Jennifer Bacik; Robert J. Motzer


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
91 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Novel therapeutics for metastatic renal
✍ Thomas E. Hutson; Robert A. Figlin πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 136 KB

## Abstract The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon Ξ±, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vas

Prognostic nomogram for sunitinib in pat
✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 3 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi

Infusional floxuridine-based therapy for
✍ David M. Reese; Michelle Corry; Eric J. Small πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 2 views

## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F